nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['majestec-2', 'mmsm', 'lenalidomide', 'daratumumab', 'teclistamab', ' lena', 'dexamethasone', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)']
congress | #ash22
emma searle , presents initial data from the ongoing phase ib majestec-2 trial, showing that the addition of teclistamab to daratumumab and lenalidomide is well tolerated and shows promising clinical activity in patients with mm. #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma